L-acetylcarnityne treatment on fragile X patients hyperactive behaviour

被引:5
作者
Calvani, M
D'Iddio, S
de Gaetano, A
Mariotti, P
Mosconi, L
Pomponi, MG
Tabolacci, E
Torrioli, MG
Vernacotola, S
Neri, G
机构
[1] Sigma Tau Pharmaceut Co, Dept Sci, I-00040 Rome, Italy
[2] Catholic Univ, Inst Genet, Dept Neuropsiquiatria Infantil, Rome, Italy
[3] Catholic Univ, CNR, Lab Biomatemat, Rome, Italy
关键词
hyperactive behaviour; L-acetylcarnitine; fragile X syndrome;
D O I
10.33588/rn.33S1.2001381
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Hyperactivity is a significant problem for almost all young males affected by fragile X syndrome (FXS), the most common inherited disease causing mental retardation. Therapeutical approaches are actually based on Central Nervous System (CNS) stimulants lacking a well defined rationale and efficacy while they further decrease the patient's limited attention span. A pilot study on 17 fragile X male treated with L-acetylcamitine (LAC) over one year, showed a significant reduction of their hyperactivity behaviour tested by the Conners Abbreviated Parent-Teacher Questionnaire. LAC rise in FXS patients derives from the hypothesis that the biochemical and physiological properties this substance has may preserve brain activity. LA Cis a small, hydrosoluble molecule that easily diffuses in the extracellular space and enters any cell in the nervous system through specific transporters. Different cerebral areas use this molecule differently to metabolize glucose and lipids to provide for ATP and neurotransmitters synthesis. The acetyl group LAC carriers represents a key metabolic signaling element possibly mediating its effect in the CNS. The erogenous administration of LAC may affect brain activity in FXS by: I) modulation of fuel partitioning for energy production, which at the mithocondrial level is associated with the Kreb's cycle metabolic role in neurotransmitter synthesis; II) remodelling of livid membrane in terms of LAC actively determining the production of polyunsaturated fatty acids; III) preferential effect on the attention component of the cholinergic system which relies on its peculiar modality of communication in the CNS Based on the above premises an explorative, double-blind, placebo controlled, multicenter study is ongoing. A total population of 160 children from nine European centers will be enrolled, The objective of this study is to determine the effect of LAC on the hyperactive behaviour of FXS children as evaluated by the administration of the Conners Abbreviated Parent Questionnaire.
引用
收藏
页码:S65 / S70
页数:6
相关论文
共 53 条
[11]   NEUROPROTECTIVE ACTIVITY OF ACETYL-L-CARNITINE - STUDIES IN-VITRO [J].
FORLONI, G ;
ANGERETTI, N ;
SMIROLDO, S .
JOURNAL OF NEUROSCIENCE RESEARCH, 1994, 37 (01) :92-96
[12]   SPATIAL MEMORY IN AGED RATS - POPULATION HETEROGENEITY AND EFFECT OF LEVOCARNITINE ACETYL [J].
GHIRARDI, O ;
GIULIANI, A ;
CAPRIOLI, A ;
RAMACCI, MT ;
ANGELUCCI, L .
JOURNAL OF NEUROSCIENCE RESEARCH, 1992, 31 (02) :375-379
[13]   EFFECT OF ACETYL-L-CARNITINE CHRONIC TREATMENT ON DISCRIMINATION MODELS IN AGED RATS [J].
GHIRARDI, O ;
MILANO, S ;
RAMACCI, MT ;
ANGELUCCI, L .
PHYSIOLOGY & BEHAVIOR, 1988, 44 (06) :769-773
[14]   LONG-TERM ACETYL-L-CARNITINE PRESERVES SPATIAL-LEARNING IN THE SENESCENT RAT [J].
GHIRARDI, O ;
MILANO, S ;
RAMACCI, MT ;
ANGELUCCI, L .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1989, 13 (1-2) :237-245
[15]  
GIARDINO L, 1993, NEUROPSYCHOPHARMACOL, V9, pS146
[16]   STUDIES ON THE METABOLIC PATHWAY OF THE ACETYL GROUP FOR ACETYLCHOLINE SYNTHESIS [J].
GIBSON, GE ;
SHIMADA, M .
BIOCHEMICAL PHARMACOLOGY, 1980, 29 (02) :167-174
[17]   Action of L-acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex [J].
Gorini, A ;
D'Angelo, A ;
Villa, RF .
NEUROCHEMICAL RESEARCH, 1998, 23 (12) :1485-1491
[18]   Energy metabolism of synaptosomal subpopulations from different neuronal systems of rat hippocampus: Effect of L-acetylcarnitine administration in vivo [J].
Gorini, A ;
D'Angelo, A ;
Villa, RF .
NEUROCHEMICAL RESEARCH, 1999, 24 (05) :617-624
[19]   Is there an astrocyte-neuron ketone body shuttle? [J].
Guzmán, M ;
Blázquez, C .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2001, 12 (04) :169-173
[20]  
HANGERMAN RJ, 1991, FRAGILE X SYNDROME D